A bispecific antibody targeting PD-L1 and TGFβR2 has shown preclinical evidence of enhancing antibody-dependent cellular cytotoxicity mediated by both PD-L1 and TGFβR2 preclinically [111] and is now in clinical trials including a glioma cohort of patients [112] (NCT02517398). This evidence concerns the gene TGFBR2 and glioma.